Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00795665 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
A Phase 2 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00795665 is a Phase 2 study that has completed, run by University of California, Davis. The registered enrollment target is 7 participants.
The verdict
NCT00795665, a Phase 2 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as carmustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with carmustine may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving bevacizumab together with carmustine works in treating patients with relapsed or progressive high-grade glioma.
Interventions
- DRUG bevacizumab
- DRUG carmustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-06 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00795665
The ClinicalTrials.gov registry entry for NCT00795665 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bevacizumab is the first listed.
NCT00795665 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00795665 about?
NCT00795665 is a clinical study titled "Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma". RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by bloc...
What is the current status of trial NCT00795665?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2008-06. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00795665?
The interventions under investigation include: bevacizumab (DRUG), carmustine (DRUG).
Who is sponsoring clinical trial NCT00795665?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.